Table 2 Comparison of baseline information of patients between high and low DGPRI groups.

From: DGPRI, a new liver fibrosis assessment index, predicts recurrence of AFP-negative hepatocellular carcinoma after hepatic resection: a single-center retrospective study

Characteristics

All patients N = 378

Low DGPRI N = 177

High DGPRI N = 201

p

Sex, n (%)

0.060

 Male

332 (87.8%)

149 (84.2%)

183 (91.0%)

 

 Female

46 (12.2%)

28 (15.8%)

18 (8.96%)

 

Age, n (%)

0.186

  < 60

229 (60.6%)

114 (64.4%)

115 (57.2%)

 

  ≥ 60

149 (39.4%)

63 (35.6%)

86 (42.8%)

 

Family history of malignant tumors, n (%)

0.743

 No

288 (76.2%)

133 (75.1%)

155 (77.1%)

 

 Yes

90 (23.8%)

44 (24.9%)

46 (22.9%)

 

Hypertension, n (%)

0.762

 No

256 (67.7%)

118 (66.7%)

138 (68.7%)

 

 Yes

122 (32.3%)

59 (33.3%)

63 (31.3%)

 

Diabetes, n (%)

0.244

 No

310 (82.0%)

150 (84.7%)

160 (79.6%)

 

 Yes

68 (18.0%)

27 (15.3%)

41 (20.4%)

 

Smoking, n (%)

0.178

 No

190 (50.3%)

96 (54.2%)

94 (46.8%)

 

 Yes

188 (49.7%)

81 (45.8%)

107 (53.2%)

 

HBV infection, n (%)

0.914

 No

111 (29.4%)

51 (28.8%)

60 (29.9%)

 

 Yes

267 (70.6%)

126 (71.2%)

141 (70.1%)

 

HCV infection, n (%)

0.995

 No

347 (91.8%)

163 (92.1%)

184 (91.5%)

 

 Yes

31 (8.20%)

14 (7.91%)

17 (8.46%)

 

BMI, n (%)

0.171

  < 28

322 (85.2%)

156 (88.1%)

166 (82.6%)

 

  ≥ 28

56 (14.8%)

21 (11.9%)

35 (17.4%)

 

Operation duration, n (%)

0.085

  ≤ 180

184 (48.7%)

95 (53.7%)

89 (44.3%)

 

  > 180

194 (51.3%)

82 (46.3%)

112 (55.7%)

 

Intraoperative blood loss, n (%)

 < 0.001

  ≤ 200

251 (66.4%)

139 (78.5%)

112 (55.7%)

 

  > 200

127 (33.6%)

38 (21.5%)

89 (44.3%)

 

Intraoperative blood transfusion, n (%)

0.043

 No

341 (90.2%)

166 (93.8%)

175 (87.1%)

 

 Yes

37 (9.79%)

11 (6.21%)

26 (12.9%)

 

Number of tumors, n (%)

0.304

 Single

350 (92.6%)

167 (94.4%)

183 (91.0%)

 

 Multiple

28 (7.41%)

10 (5.65%)

18 (8.96%)

 

Edmondson Steiner grade, n (%)

0.530

 I-II

310 (82.0%)

148 (83.6%)

162 (80.6%)

 

 III-IV

68 (18.0%)

29 (16.4%)

39 (19.4%)

 

Maximum diameter of the largest tumor, n (%)

1.000

  < 5

289 (76.5%)

135 (76.3%)

154 (76.6%)

 

  ≥ 5

89 (23.5%)

42 (23.7%)

47 (23.4%)

 

Liver capsule invasion, n (%)

1.000

 No

216 (57.1%)

101 (57.1%)

115 (57.2%)

 

 Yes

162 (42.9%)

76 (42.9%)

86 (42.8%)

 

MVI, n (%)

0.342

 No

294 (77.8%)

142 (80.2%)

152 (75.6%)

 

 Yes

84 (22.2%)

35 (19.8%)

49 (24.4%)

 

Satellite nodule, n (%)

0.051

 No

357 (94.4%)

172 (97.2%)

185 (92.0%)

 

 Yes

21 (5.56%)

5 (2.82%)

16 (7.96%)

 

TNM staging, n (%)

0.167

 I

266 (70.4%)

133 (75.1%)

133 (66.2%)

 

 II

91 (24.1%)

35 (19.8%)

56 (27.9%)

 

 III

20 (5.29%)

9 (5.08%)

11 (5.47%)

 

 IV

1 (0.26%)

0 (0.00%)

1 (0.50%)

 

BCLC staging, n (%)

0.294

 0

69 (18.3%)

31 (17.5%)

38 (18.9%)

 

 A

288 (76.2%)

140 (79.1%)

148 (73.6%)

 

 B

16 (4.23%)

4 (2.26%)

12 (5.97%)

 

 C

5 (1.32%)

2 (1.13%)

3 (1.49%)

 

Scheuer scoring system, n (%)

 < 0.001

 S0-S1

126 (33.3%)

80 (45.2%)

46 (22.9%)

 

 S2-S4

252 (66.7%)

97 (54.8%)

155 (77.1%)

 

AFP, median [IQR]

4.22 [2.55;7.08]

3.26 [2.08;6.07]

4.96 [2.90;7.84]

 < 0.001

HGB, median [IQR]

151 [142;160]

151 [141;158]

152 [142;162]

0.123

PLT, median [IQR]

164 [129;202]

183 [157;221]

141 [103;177]

 < 0.001

ALT, median [IQR]

26.0 [20.0;40.0]

22.2 [17.0;31.0]

30.0 [23.0;46.0]

 < 0.001

AST, median [IQR]

25.0 [20.0;33.0]

22.0 [19.0;27.2]

28.0 [22.0;39.0]

 < 0.001

TBIL, median [IQR]

13.6 [9.90;17.2]

11.9 [8.40;14.9]

15.4 [11.8;19.2]

 < 0.001

DBIL, median [IQR]

4.50 [3.40;5.80]

3.70 [2.80;4.70]

5.40 [4.20;6.60]

 < 0.001

ALB, median [IQR]

44.5 [41.6;46.8]

44.4 [41.9;46.5]

44.5 [41.4;47.4]

0.498

LDH, median [IQR]

169 [147;191]

159 [142;183]

173 [153;195]

0.001

GGT, median [IQR]

40.0 [26.0;63.9]

26.0 [20.1;37.0]

60.0 [41.0;89.0]

 < 0.001

Major hepatectomy, n (%)

0.890

 No

315 (83.3%)

148 (83.6%)

167 (83.1%)

 

 Yes

63 (16.7%)

29 (16.4%)

34 (16.9%)

 

Adjuvant therapy, n (%)

0.614

 No

299 (79.1%)

142 (80.2%)

157 (78.1%)

 

 Yes

79 (20.9%)

35 (19.8%)

44 (21.9%)

 
  1. DGPRI DBIL-GPR index. HBV hepatitis B virus, HCV hepatitis C virus, BMI body mass index, MVI microvascular invasion, AJCC-TNM American Joint Committee on Cancer tumor–node–metastasis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, HGB hemoglobin, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, ALB albumin, LDH lactate dehydrogenase, DBIL direct bilirubin, GGT gamma.
Back to article page